Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Pioglitazone

First Posted Date: 2014-10-28

Last Posted Date: 2014-10-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02276365

Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan high
Drug: Telmisartan low
Drug: Hydrochlorothiazide (HCTZ)
Other: Japanese meal

First Posted Date: 2014-10-28

Last Posted Date: 2014-10-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02276378

Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS - rising dose
Drug: Placebo

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT02273414

Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER
Other: Standardized breakfast

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT02273492

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER (new formulation II - high)
Drug: Asasantin ER (present commercial formulation)
Drug: Asasantin ER (new formulation I - low)
Drug: Asasantin ER (new formulation III - medium)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 19

Registration Number: NCT02273557

Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Songha® Night
Drug: Oxazepam
Drug: Placebo

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 54

Registration Number: NCT02273453

Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Drug: Placebo
Drug: Theophylline

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02273440

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin (ER)
Drug: Persantin
Drug: Acetyl salicylic acid (ASA)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02273505

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 6727

First Posted Date: 2014-10-24

Last Posted Date: 2023-10-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT02273388

Locations: 🇧🇪
1230.1.32002 Boehringer Ingelheim Investigational Site, Brussels, Belgium
🇧🇪
1230.1.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER, new formulation
Drug: Asasantin ER, present commercial formulation

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273531

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy